Literature DB >> 27624571

High prevalence of ESBL-producing Escherichia coli and Klebsiella pneumoniae in community-onset bloodstream infections in China.

Jingjing Quan1, Dongdong Zhao1, Lilin Liu1, Yan Chen1, Jiancang Zhou2, Yan Jiang1, Xiaoxing Du1, Zhihui Zhou1, Murat Akova3, Yunsong Yu4,5.   

Abstract

OBJECTIVES: Community-onset bloodstream infections (COBSIs) caused by ESBL-producing Escherichia coli (ESBL-EC) and ESBL-producing Klebsiella pneumoniae (ESBL-KP) are increasing globally. This study aimed to investigate the epidemiology and risk factors of ESBL-EC and ESBL-KP in COBSIs in China.
METHODS: A prospective, multicentre study was performed in 28 tertiary hospitals from September 2013 to November 2014. All isolates and ESBLs were microbiologically characterized. A statistical analysis of risk factors was performed using binary logistic regression. The trial was registered with ClinicalTrials.gov (NCT01961206).
RESULTS: A total of 919 consecutive episodes of COBSIs were reported and 640 E. coli and 279 K. pneumoniae isolates (non-duplicate) were collected. According to the criteria, 662 (72.0%) cases were classified as having community-acquired bloodstream infections, while the remaining 257 (28.0%) were classified as having healthcare-associated bloodstream infections. The proportions of ESBL producers were 55.5% (355/640) among E. coli isolates and 16.5% (46/279) among K. pneumoniae isolates, respectively. Healthcare-associated infections, obstructive urinary tract disease, previous surgical history and use of a cephalosporin antibiotic within 3 months were independent predictors of COBSIs caused by ESBL-EC. Heart failure was the only independent risk factor for COBSIs due to ESBL-KP. Age was not independently associated with infections caused by ESBL producers. CTX-M-14 was the most common ESBL genotype and was widespread throughout the country.
CONCLUSIONS: ESBL producers are highly prevalent in COBSIs in China, especially among cases caused by E. coli. For these resistant pathogens, clinicians should consider adequate empirical therapy, and different risk factors for prediction should be used in this country.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27624571     DOI: 10.1093/jac/dkw372

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  34 in total

Review 1.  Antimicrobial Resistance in ESKAPE Pathogens.

Authors:  David M P De Oliveira; Brian M Forde; Timothy J Kidd; Patrick N A Harris; Mark A Schembri; Scott A Beatson; David L Paterson; Mark J Walker
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

2.  Improved Accuracy of Cefepime Susceptibility Testing for Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae with an On-Demand Digital Dispensing Method.

Authors:  Kenneth P Smith; Thea Brennan-Krohn; Susan Weir; James E Kirby
Journal:  J Clin Microbiol       Date:  2016-11-30       Impact factor: 5.948

3.  Risk factors for antibiotic resistance and mortality in patients with bloodstream infection of Escherichia coli.

Authors:  Shunjin Zhao; Yingjing Wu; Zhong Dai; Yijing Chen; Xiaojuan Zhou; Jun Zhao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-02-21       Impact factor: 3.267

4.  Safety and efficacy of the Seraph® 100 Microbind® Affinity Blood Filter to remove bacteria from the blood stream: results of the first in human study.

Authors:  Gabriele Eden; Julius J Schmidt; Stefan Büttner; Philipp Kümpers; Carsten Hafer; Alexandros Rovas; Benjamin Florian Koch; Bernhard M W Schmidt; Jan T Kielstein
Journal:  Crit Care       Date:  2022-06-17       Impact factor: 19.334

Review 5.  Review of Antibiotic Resistance in the Indian Ocean Commission: A Human and Animal Health Issue.

Authors:  Noellie Gay; Olivier Belmonte; Jean-Marc Collard; Mohamed Halifa; Mohammad Iqbal Issack; Saindou Mindjae; Philippe Palmyre; Abdul Aziz Ibrahim; Harena Rasamoelina; Loïc Flachet; Laurent Filleul; Eric Cardinale
Journal:  Front Public Health       Date:  2017-07-06

6.  A putative multi-replicon plasmid co-harboring beta-lactamase genes blaKPC-2, blaCTX-M-14 and blaTEM-1 and trimethoprim resistance gene dfrA25 from a Klebsiella pneumoniae sequence type (ST) 11 strain in China.

Authors:  Yu Tang; Pinghua Shen; Wei Liang; Jialin Jin; Xiaofei Jiang
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

7.  Multi-level analysis of bacteria isolated from inpatients in respiratory departments in China.

Authors:  Xiang Tang; Meng Xiao; Chao Zhuo; Yingchun Xu; Nanshan Zhong
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

8.  Clinical and Microbiological Characteristics of a Community-Acquired Carbapenem-Resistant Escherichia coli ST410 Isolate Harbouring blaNDM-5-Encoding IncX3-Type Plasmid From Blood.

Authors:  Ji-Na Gu; Lin Chen; Xing-Bei Weng; Xiao-Yan Yang; Dan-Mei Pan
Journal:  Front Med (Lausanne)       Date:  2021-06-11

9.  Antibacterial effect evaluation of moxalactam against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae with in vitro pharmacokinetics/pharmacodynamics simulation.

Authors:  Chen Huang; Beiwen Zheng; Wei Yu; Tianshui Niu; Tingting Xiao; Jing Zhang; Yonghong Xiao
Journal:  Infect Drug Resist       Date:  2018-01-15       Impact factor: 4.003

10.  Clinical Characteristics, Risk Factors, and Outcomes of Patients with Polymicrobial Klebsiella pneumoniae Bloodstream Infections.

Authors:  Feizhen Song; Kai Zhang; Jianjiang Huang; Zhenhua Qian; Hongwei Zhou; Jiachang Cai; Cheng Zheng; Feifei Zhou; Wei Cui; Gensheng Zhang
Journal:  Biomed Res Int       Date:  2021-06-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.